The China National Medical Product Administration (NMPA) has approved CASI Pharmaceuticals’ (NASDAQ:CASI) clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL) submitted by its partner Juventas Cell Therapy Ltd.
The Company expects to start enrolling patients in early 2020.
CASI has previously acquired exclusive worldwide commercial rights to CNCT19 from Juventas.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.